Xpert® MTB/XDR

Home / Tests / TB & Emerging Infectious Diseases

Xpert® MTB/XDR

Simplifying TB drug susceptibility testing utilizing increased multiplexing capability with 10 color GeneXpert® technology

Test pack size(s)

10 Tests

GXMTB/XDR-10

Qty

Unit price

Subtotal

USD

Total

Error adding items to cart. If this error persists, please contact Digital Support

List name

Label

Having trouble? Contact Cepheid Digital Support

The Need

In 2022, only 43% of the total estimated multidrug-resistant Tuberculosis (MDR-TB) incident cases were diagnosed and enrolled on treatment regimen¹
Only 47% of the total notified MDR-TB cases were tested for resistance to fluoroquinolones¹
Increase access to rapid and extended drug resistance profiling for all TB-positive cases to rule out MDR/pre-XDR^{^} TB2

1 World Health Organization Tuberculosis Report 2023--https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023/tb-disease-burden/1-3-drug-resistant-tb. Accessed January 2024.
2 Global Plan to End TB, STOP TB Report- https://omnibook.com/api/export/1.0/dc664b3a-14b4-4cc0-8042-ea8f27e902a6/-1/0/pdf^ Pre-XDR: Pre-Extensive Drug Resistant TB
^ Pre-XDR: Pre-Extensive Drug Resistant TB

The Solution

The Xpert MTB/XDR test enables rapid molecular DST. When combined with the frontline Xpert MTB/RIF Ultra test, it sets new standards by detecting mutations associated with resistance to isoniazid (INH), fluoroquinolones (FLQ), second-line injectable drugs (SLIDs), and ethionamide (ETH) in a single test.

Fast time to result for molecular DST
Results in <90 minutes
Same easy-to-use process as the Xpert MTB/RIF Ultra test
Run on existing GeneXpert® platforms equipped with 10-color modules

The Impact

Upfront molecular DST for all TB-positive cases enables optimized treatment in a single visit
Increased access to drug-resistance testing with Xpert MTB/XDR help notify more people affected with MDR and Pre-XDR TB³
The Xpert MTB/XDR assay provides the capability to differentiate between high and low-level resistance to INH and FLQ, which is important for determining therapeutic options and individualized treatment regimens⁴

3 Adam Penn-Nicholson et al. 2022 https://www.medrxiv.org/content/10.1101/2021.05.06.21256505v1.full.pdf
4 L Saderi, et al. 2022 https://www.archbronconeumol.org/es-pdf-S0300289622004987